Xenon Pharmaceuticals (XENE) Competitors $38.56 +0.36 (+0.94%) As of 12:45 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock XENE vs. ASND, MRNA, VTRS, QGEN, ROIV, LNTH, RVMD, BBIO, LEGN, and TGTXShould you be buying Xenon Pharmaceuticals stock or one of its competitors? The main competitors of Xenon Pharmaceuticals include Ascendis Pharma A/S (ASND), Moderna (MRNA), Viatris (VTRS), Qiagen (QGEN), Roivant Sciences (ROIV), Lantheus (LNTH), Revolution Medicines (RVMD), BridgeBio Pharma (BBIO), Legend Biotech (LEGN), and TG Therapeutics (TGTX). These companies are all part of the "pharmaceutical products" industry. Xenon Pharmaceuticals vs. Ascendis Pharma A/S Moderna Viatris Qiagen Roivant Sciences Lantheus Revolution Medicines BridgeBio Pharma Legend Biotech TG Therapeutics Xenon Pharmaceuticals (NASDAQ:XENE) and Ascendis Pharma A/S (NASDAQ:ASND) are both medical companies, but which is the superior business? We will contrast the two businesses based on the strength of their profitability, dividends, institutional ownership, risk, community ranking, valuation, media sentiment, earnings and analyst recommendations. Does the media prefer XENE or ASND? In the previous week, Xenon Pharmaceuticals had 2 more articles in the media than Ascendis Pharma A/S. MarketBeat recorded 13 mentions for Xenon Pharmaceuticals and 11 mentions for Ascendis Pharma A/S. Xenon Pharmaceuticals' average media sentiment score of 1.22 beat Ascendis Pharma A/S's score of 1.07 indicating that Xenon Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Xenon Pharmaceuticals 7 Very Positive mention(s) 0 Positive mention(s) 4 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Ascendis Pharma A/S 4 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Do analysts rate XENE or ASND? Xenon Pharmaceuticals currently has a consensus target price of $56.78, suggesting a potential upside of 47.25%. Ascendis Pharma A/S has a consensus target price of $204.67, suggesting a potential upside of 23.11%. Given Xenon Pharmaceuticals' stronger consensus rating and higher possible upside, research analysts clearly believe Xenon Pharmaceuticals is more favorable than Ascendis Pharma A/S.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Xenon Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 10 Buy rating(s) 0 Strong Buy rating(s) 3.00Ascendis Pharma A/S 0 Sell rating(s) 1 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 2.93 Which has better earnings and valuation, XENE or ASND? Xenon Pharmaceuticals has higher earnings, but lower revenue than Ascendis Pharma A/S. Ascendis Pharma A/S is trading at a lower price-to-earnings ratio than Xenon Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioXenon Pharmaceuticals$9.43M312.99-$182.39M-$3.02-12.77Ascendis Pharma A/S$363.64M27.87-$409.12M-$7.10-23.42 Is XENE or ASND more profitable? Xenon Pharmaceuticals has a net margin of 0.00% compared to Ascendis Pharma A/S's net margin of -104.54%. Ascendis Pharma A/S's return on equity of 0.00% beat Xenon Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Xenon PharmaceuticalsN/A -24.69% -23.68% Ascendis Pharma A/S -104.54%N/A -39.23% Do insiders & institutionals believe in XENE or ASND? 95.4% of Xenon Pharmaceuticals shares are held by institutional investors. 5.5% of Xenon Pharmaceuticals shares are held by insiders. Comparatively, 40.0% of Ascendis Pharma A/S shares are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term. Does the MarketBeat Community believe in XENE or ASND? Ascendis Pharma A/S received 24 more outperform votes than Xenon Pharmaceuticals when rated by MarketBeat users. However, 69.74% of users gave Xenon Pharmaceuticals an outperform vote while only 66.87% of users gave Ascendis Pharma A/S an outperform vote. CompanyUnderperformOutperformXenon PharmaceuticalsOutperform Votes42469.74% Underperform Votes18430.26% Ascendis Pharma A/SOutperform Votes44866.87% Underperform Votes22233.13% Which has more volatility & risk, XENE or ASND? Xenon Pharmaceuticals has a beta of 1.21, meaning that its share price is 21% more volatile than the S&P 500. Comparatively, Ascendis Pharma A/S has a beta of 0.54, meaning that its share price is 46% less volatile than the S&P 500. SummaryXenon Pharmaceuticals beats Ascendis Pharma A/S on 13 of the 18 factors compared between the two stocks. Get Xenon Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for XENE and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart XENE vs. The Competition Export to ExcelMetricXenon PharmaceuticalsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$2.95B$6.72B$5.49B$7.97BDividend YieldN/A3.05%5.11%4.23%P/E Ratio-13.677.3622.6118.58Price / Sales312.99241.71397.51103.15Price / CashN/A65.8538.1834.62Price / Book2.726.486.704.26Net Income-$182.39M$143.43M$3.22B$248.31M7 Day Performance0.94%1.69%1.26%1.34%1 Month Performance25.85%6.58%3.73%3.92%1 Year Performance-9.25%-2.63%15.82%5.33% Xenon Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)XENEXenon Pharmaceuticals2.5924 of 5 stars$38.56+0.9%$56.78+47.2%-6.0%$2.95B$9.43M-13.67210Upcoming EarningsOptions VolumePositive NewsASNDAscendis Pharma A/S2.3116 of 5 stars$161.15-2.4%$204.67+27.0%+23.1%$9.83B$363.64M-22.70640Positive NewsMRNAModerna4.4322 of 5 stars$25.13+1.7%$58.70+133.6%-74.1%$9.72B$3.20B-2.713,900Earnings ReportNews CoverageGap DownVTRSViatris1.835 of 5 stars$7.57+0.1%$10.50+38.7%-27.2%$9.04B$14.74B-10.2337,000Upcoming EarningsQGENQiagen3.6936 of 5 stars$40.51-0.5%$47.83+18.1%+4.0%$9.01B$1.98B112.806,030Upcoming EarningsAnalyst RevisionROIVRoivant Sciences2.2052 of 5 stars$10.04-1.1%$17.50+74.3%+6.6%$7.16B$122.59M-66.93860Positive NewsLNTHLantheus3.9711 of 5 stars$100.62-0.7%$129.43+28.6%+56.8%$6.89B$1.53B16.74700Upcoming EarningsPositive NewsRVMDRevolution Medicines3.762 of 5 stars$36.56-0.5%$66.67+82.3%+8.3%$6.80B$742,000.00-10.18250Upcoming EarningsAnalyst ForecastPositive NewsBBIOBridgeBio Pharma4.5481 of 5 stars$33.51-1.1%$53.00+58.2%+49.7%$6.37B$221.90M-11.76400Earnings ReportAnalyst ForecastOptions VolumeNews CoverageLEGNLegend Biotech2.6407 of 5 stars$32.24-1.7%$79.00+145.0%-20.1%$5.92B$627.24M-33.941,070TGTXTG Therapeutics3.3232 of 5 stars$36.97-3.5%$40.67+10.0%+233.2%$5.81B$329.00M-369.66290Upcoming EarningsNews CoveragePositive News Related Companies and Tools Related Companies Ascendis Pharma A/S Alternatives Moderna Alternatives Viatris Alternatives Qiagen Alternatives Roivant Sciences Alternatives Lantheus Alternatives Revolution Medicines Alternatives BridgeBio Pharma Alternatives Legend Biotech Alternatives TG Therapeutics Alternatives Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:XENE) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredThis Is How Empires FallThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | Sponsored[Action Required] Claim Your FREE IRS Loophole GuideThis shouldn't surprise anyone who's been paying attention, but... Pres. Trump may be about to unleash the ...Colonial Metals | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Xenon Pharmaceuticals Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Xenon Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy XENE Stock Free XENE Stock Alerts